RBC Capital Remains Bullish on Insmed Incorporated (INSM)

Insmed Incorporated (NASDAQ:INSM) is one of the best stocks to invest in right now. On September 19, RBC Capital analyst Leonid Timashev maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) and set a price target of $138.00.

Insmed (INSM) Soars After Raising $650 million

Insmed Incorporated (NASDAQ:INSM) reported in its fiscal Q2 2025 results that total revenue for ARIKAYCE reached $107.4 million for the quarter, reflecting a growth of 19% over fiscal Q2 2024.

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.

While we acknowledge the potential of INSM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INSM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.